Efficacy and Safety of Erenumab in Pediatric Subjects With Episodic Migraine



Status:Not yet recruiting
Conditions:Migraine Headaches
Therapuetic Areas:Neurology
Healthy:No
Age Range:6 - 17
Updated:2/13/2019
Start Date:June 6, 2019
End Date:June 28, 2023
Contact:Amgen Call Center
Email:medinfo@amgen.com
Phone:866-572-6436

Use our guide to learn which trials are right for you!

A Phase 3, Randomized, Double-blind,Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])

This study will evaluate the efficacy and safety of erenumab in migraine prevention in
children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine. The study
hypothesis is that in pediatric subjects with episodic migraine, the combined erenumab dose
group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly
migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).

This study is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group study
to evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12
years) and adolescents (12 to <18 years) with episodic migraine.

The trial consists of four phases: screening (up to 3 weeks of initial screening and a 4-week
prospective baseline phase); the double-blind treatment phase (24 weeks) in which
participants receive placebo or Erenumab dose 1, dose 2 or dose 3 (based on participant's
body weight) via subcutaneous injection once a month; the optional dose level blinded
extension phase (40 weeks), in which all participants are assigned to receive dose 1, dose 2
or dose 3 of Erenumab; and a 12 weeks safety follow-up phase (16 weeks after the last dose of
investigational drug).

The study intends to enroll 456 participants (376 adolescents and up to 80 children).

Inclusion Criteria:

- Children (6 to less than 12 years of age) or adolescent (12 to less than 18 years of
age) at the time of signing, if developmentally appropriate, the formal assent to
participate to the study.

- Subject's parent or legal representative has provided written informed consent before
initiation of any study specific activities/procedures.

- History of migraine (with or without aura) for greater than or equal to 12 months
before screening according to the IHS Classification ICHD-3 (Headache Classification
Committee of the International Headache Society, 2013) ICHD-3 specifications for
pediatric migraine (subjects aged less than 18 years), should be considered for the
diagnosis of migraine

- History of less than 15 headache days per month of which greater than or equal to 4
headache days were assessed by the subject as migraine days per month in each of the 3
months prior to screening.

- Migraine frequency: greater than or equal to 4 and less than 15 migraine days during
the baseline phase based on the eDiary calculations.

Key Exclusion Criteria:

- History of cluster headache or hemiplegic migraine headache.

- No therapeutic response with greater than 2 medication categories for prophylactic
treatment of migraine after an adequate therapeutic trial.

No therapeutic response is defined as no reduction in headache frequency, duration, or
severity after administration of the medication for at least 6 weeks at the
generally-accepted therapeutic dose(s) based on the investigator's assessment.

- History of suicidal behavior or the subject is at risk of self-harm or harm to others.

- History of major psychiatric disorder. Subjects with anxiety disorder and/or mild
major depressive disorder (with PHQ-A score 9) are permitted in the study if they are
considered by the investigator to be stable and are taking no more than 1 medication
for each disorder. Subjects must have been on a stable dose within the 3 months before
the start of the baseline phase.
We found this trial at
19
sites
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
Amherst, NY
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Brussels,
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Colorado Springs, Colorado 80910
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
?
mi
from
Marshfield, WI
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Washington,
Click here to add this to my saved trials
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
?
mi
from
Worcester, MA
Click here to add this to my saved trials